266. Familial mediterranean fever Clinical trials / Disease details

Clinical trials : 28 / Drugs : 22 - (DrugBank : 5) / Drug target genes : 14 - Drug target pathways : 59

diseases per page:

Showing 1 to 10 of 28 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05448391 (ClinicalTrials.gov)	September 13, 2022	1/7/2022	A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)	An Open-label, Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of RIST4721 in Subjects ...	Familial Mediterranean Fever	Drug: RIST4721	Aristea Therapeutics, Inc.	NULL	Withdrawn	18 Years	74 Years	All	0	Phase 2	Israel;Turkey
2	NCT05418686 (ClinicalTrials.gov)	July 2022	10/6/2022	Study of Colchicine Resistance in Familial Mediterranean Fever	Study Of Colchicine Resistance In Familial Mediterranean Fever	Mediterranean Fever;Colchicine Resistance	Biological: Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patient ...	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	12 Years	N/A	All	30	N/A	France
3	NCT05190991 (ClinicalTrials.gov)	October 5, 2021	3/11/2021	Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchi ...	An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Pre ...	Familial Mediterranean Fever;FMF	Biological: RPH-104	R-Pharm International, LLC	Atlant Clinical LLC;Center for Pharmaceutical Analytics LLC;Unimed Laboratories CJSC;Data Management ...	Recruiting	18 Years	80 Years	All	60	Phase 2	Armenia;Georgia;Russian Federation
4	NCT04478409 (ClinicalTrials.gov)	July 21, 2021	16/7/2020	Characterization of a Functional Test for Mediterranean Family Fever Screening - 2	Characterization of a Functional Test for Mediterranean Family Fever Screening - 2	Familial Mediterranean Fever;MEFV Gene Mutation	Biological: one additional blood sample during a planned blood test	Hospices Civils de Lyon	NULL	Recruiting	4 Years	N/A	All	160		France
5	NCT05092776 (ClinicalTrials.gov)	April 29, 2021	9/9/2021	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects ...	International, Multicenter, Double Blind, Placebo-controlled, Randomized Clinical Study of Efficacy ...	Familial Mediterranean Fever;FMF	Biological: RPH-104;Drug: Placebo	R-Pharm International, LLC	Data Management 365;Atlant Clinical LLC;R-Pharm;Center of Pharmaceutical Analytics LLC;Unimed Labora ...	Recruiting	18 Years	N/A	All	60	Phase 2	Armenia;Georgia;Russian Federation
6	JPRN-UMIN000032557	2018/09/01	30/05/2018	An open-label continuation trial of tocilizumab for familial Mediterranean feverwith colchicine inef ...	An open-label continuation trial of tocilizumab for familial Mediterranean feverwith colchicine inef ...	familial Mediterranean fever	Tocilizumab	Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasak ...	NULL	Complete: follow-up complete	12years-old	Not applicable	Male and Female	24	Not selected	Japan
7	NCT03446209 (ClinicalTrials.gov)	April 23, 2018	11/12/2017	Tocilizumab for the Treatment of Familial Mediterranean Fever	Tocilizumab for the Treatment of Familial Mediterranean Fever- A Randomized, Doubleblind, Phase II P ...	Familial Mediterranean Fever	Drug: Tocilizumab Infusion RoAcemtra (EU);Drug: 0.9% physiological saline	University Hospital Tuebingen	NULL	Completed	18 Years	64 Years	All	30	Phase 2	Germany
8	JPRN-UMIN000028010	2018/03/01	07/07/2017	Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant fa ...	Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant fa ...	familial Mediterranean fever	Tocilizumab Placebo	Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasak ...	NULL	Complete: follow-up complete	12years-old	Not applicable	Male and Female	24	Not selected	Japan
9	EUCTR2016-004505-13-DE (EUCTR)	27/11/2017	21/08/2017	Tocilizumab for the Treatment of Familial Mediterranean Fever	Tocilizumab for the Treatment of Familial Mediterranean Fever– A randomized, doubleblind, phase II p ...	Adult patients with Familial Mediterranean Fever, who have active disease MedDRA version: 20.0;Level ...	Trade Name: RoActemra ® 20mg/ml Konzentrat INN or Proposed INN: INN-Tocilizumab Other descriptive name: ...	University Hospital Tuebingen	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	Germany
10	EUCTR2013-004291-35-NL (EUCTR)	07/10/2014	24/07/2014	Study of efficacy and safety of canakinumab in patients with Hereditary Periodic Fevers	A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Peri ...	Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) MedDRA version: 19.0;Level: PT;Classification cod ...	Trade Name: Ilaris Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3	United States;Greece;Finland;Spain;Ireland;Turkey;Russian Federation;Israel;Italy;Switzerland;United ...

First Previous1 2 3Next Last